Shares of health-care companies rose as fears about regulatory risks and pressures on drug prices subsided somewhat.
Eli Lilly's lung-cancer treatment Alimta, which had $1.1 billion in U.S. sales last year, could have a generic competitor if a patent board accepts a challenge.
Continue Reading Below
Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
May 23, 2017 17:11 ET (21:11 GMT)